Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02404805 · ClinicalTrials.gov registry record · NA
Drug Interaction Potential Between Dolutegravir and Simeprevir in HIV/HCV Seronegative Volunteers
A NA study, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- NA
- Development phase
- 25
- Enrollment target
NCT02404805 is a NA study that has completed, run by University of Colorado, Denver. The registered enrollment target is 25 participants.
The verdict
NCT02404805, a NA study, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- NA
- Development phase
- 25 participants
- Enrollment target
Study Summary
The investigator believes simeprevir concentrations are unchanged when administered in combination with dolutegravir relative to administration alone. The investigator believes dolutegravir concentrations are unchanged when administered in combination with simeprevir. Additionally, the investigator believes simeprevir and dolutegravir are safe when administered alone and in combination.
Interventions
- DRUG dolutegravir
- DRUG simeprevir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2016-02 |
| Est. Completion | 2016-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02404805
The ClinicalTrials.gov registry entry for NCT02404805 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which dolutegravir is the first listed.
NCT02404805 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02404805 about?
NCT02404805 is a clinical study titled "Drug Interaction Potential Between Dolutegravir and Simeprevir in HIV/HCV Seronegative Volunteers". The investigator believes simeprevir concentrations are unchanged when administered in combination with dolutegravir relative to administration alone. The investigator believes dolutegravir concentrations are unchanged when administered in combination with simeprevir. Additionally, the investigator ...
What is the current status of trial NCT02404805?
This trial is currently completed. It is a NA study. The enrollment target is 25 participants. The study started on 2016-02. Estimated completion is 2016-10.
What interventions are being tested in trial NCT02404805?
The interventions under investigation include: dolutegravir (DRUG), simeprevir (DRUG).
Who is sponsoring clinical trial NCT02404805?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.